US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer
The latest approval was based on the findings from the Phase II DESTINY-Lung02 trial of Enhertu.
Oncology
Latest in
Oncology
US FDA grants approval for Orion-Bayer’s Nubeqa combo for prostate cancer
The darolutamide combination treatment substantially lowered mortality risk by 32.5% in mHSPC patients.
AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer
The approval was based on findings from the Phase III DESTINY-Breast04 trial of Enhertu.
EC grants approval for Merck-AstraZeneca’s Lynparza for breast cancer
The approval was based on the Phase III OlympiA clinical trial of Lynparza versus placebo.
Poseida and Roche to develop cell therapies for hematologic cancers
Poseida could get research, development, launch and net sales milestones and other payments totalling up to $6bn.
Gilead reports 1% rise in revenue for Q2 2022
Non-GAAP diluted EPS dropped 13% to $1.58 in the second quarter of this year.
Rigel and Forma enter licence deal for acute myeloid leukaemia therapy
In a Phase II registrational study in mIDH1 R/R AML patients, olutasidenib showed a strong duration of response.
AbbVie reports 4.5% rise in Q2 2022 net revenues
The company has provided an adjusted diluted EPS guidance range of $13.78 to $13.98 for the full-year 2022.